Healthcare
Live Price
Offline$16.63
-0.48% today
1Y Change
+11.15%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viridian Therapeutics, Inc. (VRDN) is a Healthcare stock with a market cap of $1.19B and listed on NASDAQ. The stock last traded around $16.63 and up 11.1% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +23359.9%, EPS growth of +16.6%, a dividend yield of 0.0%. What stands out right now is revenue +23359.9%, EPS +16.6%, free cash flow -18.9% with operating margin -512.9% and ROIC -43.8%. Valuation already assumes a fairly strong business story at price/sales 16.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRDN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRDN Max Drawdown
-60.63%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRDN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.0M
+67.2% YoY
FY Net Income
-$79.4M
+38.9% YoY
Free Cash Flow
-$54.9M
+42.0% YoY
Revenue Growth
+23359.9%
EPS Growth
+16.6%
Gross Margin
99.5%
Net Margin
-483.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 71M | 302K | 314K | 2M | 3M |
| Gross Profit | 70M | 302K | 314K | 2M | 3M |
| Operating Income | -363M | -299M | -254M | -134M | -80M |
| EBITDA | -336M | -266M | -235M | -129M | -79M |
| Net Income | -343M | -270M | -238M | -130M | -79M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 212M | 100M | 103M | 156M | 42M |
| Total Assets | 899M | 742M | 490M | 435M | 204M |
| Total Liabilities | 177M | 71M | 48M | 40M | 16M |
| Shareholder Equity | 722M | 672M | 442M | 395M | 188M |
| Total Debt | 51M | 21M | 21M | 5M | 520K |
| Net Debt | -162M | -78M | -82M | -150M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55M
+41.8% YoY
Capital Expenditures
338K
+57.6% YoY
Free Cash Flow
55M
+42.0% YoY
Key ratios
Gross Margin
99.5%
Operating Margin
-512.9%
Net Margin
-483.6%
ROE
-58.4%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.